This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Video: Joe Salvani Discusses Significance Of Cleveland BioLabs Radiation Antidote To Nuclear Crisis In Fukushima, Japan

NEW YORK, NY -- (Marketwire) -- 03/16/11 -- Cleveland BioLabs is a biotechnology company focused on the development of innovative drugs to treat cancer and protect healthy tissues from radiation poisoning caused by a nuclear explosion or cancer treatment.

Japan's nuclear crisis has put Cleveland BioLabs lead drug, known as CBLB502, in the spotlight as the risks of a catastrophe are grave and growing with the effects of a nuclear meltdown. Although the company's radiation treatment is still in development, it has been fast-tracked by U.S. FDA and is expected to be approved in the U.S. in late 2012 or early 2013. CBLB502 has also been granted orphan status and is estimated to be years ahead of a drug being developed by Onconova called Ex-RAD.

Joe Salvani, an authority in biotechnology who began his career on Wall Street as Senior Vice President and Chemical Industry Analyst at Goldman Sachs, discussed the significance of Cleveland BioLabs drug as a radiation antidote and the near-term outlook for the company in an interview with Executive Video that can be watched here.

"Given the recent potential nuclear plant melt down at the Daiichi nuclear power plant in Fukushima, Japan, it is my belief that Cleveland BioLabs will receive emergency use authorization from the appropriate US Governmental entities to allow the company to donate thousands of doses of CBLB502 to the Japanese authorities," said Mr. Salvani.

CBLB502 has proven to be safe in over 150 human beings and extremely efficacious as a radiation antidote in nearly 1,000 primates in testing. Given the state of emergency in Japan, it's possible that CBLB502 is the only drug that could help the Japanese security forces and power plant workers as they continue to either contain or clean up the six nuclear cores at the affected power plant. The clean-up effort is expected to take at least 12 months.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,119.47 +67.74 0.40%
S&P 500 1,984.91 +11.28 0.57%
NASDAQ 4,459.69 +34.9860 0.79%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs